Contineum Therapeutics (CTNM) Shares Outstanding (2023 - 2026)

Contineum Therapeutics' Shares Outstanding (Entity) history runs 4 years deep, the most recent figure standing at $37.3 million for Q1 2026.

• On a quarterly basis, Shares Outstanding (Entity) rose 44.32% year-over-year to $37.3 million in Q1 2026; TTM through Mar 2026 was $37.3 million, a 44.32% increase from a year earlier, with the FY2025 full-year figure at $27.7 million, up 43.14% from the prior year.
• Shares Outstanding (Entity) advanced to $37.3 million in Q1 2026 per CTNM's latest filing, from $27.7 million in the prior quarter.
• Across five years, Shares Outstanding (Entity) topped out at $37.3 million in Q1 2026 and bottomed at $2.3 million in Q4 2023.
• The 4-year median for Shares Outstanding (Entity) is $23.1 million (2025), against an average of $20.8 million.
• Biggest YoY gain for Shares Outstanding (Entity) was 985.02% in 2025; the steepest drop was 10.22% in 2025.
• Year by year, Shares Outstanding (Entity) stood at $2.3 million in 2023, then jumped by 723.68% to $19.4 million in 2024, then surged by 43.14% to $27.7 million in 2025, then surged by 34.79% to $37.3 million in 2026.
• Per Business Quant, the three latest CTNM Shares Outstanding (Entity) figures stand at $37.3 million (Q1 2026), $27.7 million (Q4 2025), and $23.1 million (Q3 2025).